8a0acec7-896e-4c91-8ce7-dc64de45b53d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- MYC_TARGETS_V2+0.280
- PEROXISOME+0.210
- BILE_ACID_METABOLISM+0.190
- ESTROGEN_RESPONSE_EARLY+0.180
- FATTY_ACID_METABOLISM+0.180
- GLYCOLYSIS+0.170
- WNT_BETA_CATENIN_SIGNALING+0.170
- XENOBIOTIC_METABOLISM+0.170
Top 10 suppressed
- ANGIOGENESIS-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INFLAMMATORY_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- UV_RESPONSE_DN-0.320
- INTERFERON_ALPHA_RESPONSE-0.290
- KRAS_SIGNALING_UP-0.290
- IL6_JAK_STAT3_SIGNALING-0.280
- MYOGENESIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ULC1533T_S61 | — | cohortA2 | 0.807 |
| 2 | TCGA-CV-A6JY-01A-11R-A31N-07 | — | — | 0.805 |
| 3 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.794 |
| 4 | 68fda9a5-c6eb-4445-91f7-bd0078080b9d | — | — | 0.793 |
| 5 | SRR4296082 | — | cohortA1 | 0.792 |
| 6 | 72c16603-1f6c-479c-8cf0-95d499f328be | — | — | 0.790 |
| 7 | SRR6013506 | — | cohortA2 | 0.781 |
| 8 | X08d41e55.6d66.4e03.9dc3.3743f3da0453 | — | cohortA2 | 0.778 |
| 9 | TCGA-ZF-AA4U-01A-11R-A38B-07 | — | — | 0.777 |
| 10 | SRR10900577 | — | — | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |